# S-flurbiprofen Bioavailability Trial to Compare a Newly Developed Patch vs. a Marketed Tablet

> **NCT04505787** · PHASE1 · COMPLETED · sponsor: **SocraTec R&D GmbH** · enrollment: 26 (actual)

## Conditions studied

- Comparative Bioavailability

## Interventions

- **DRUG:** Esflurbiprofen hydrogel patch 165 mg (EFHP)
- **DRUG:** Froben 100 mg comprimidos revestidos

## Key facts

- **NCT ID:** NCT04505787
- **Lead sponsor:** SocraTec R&D GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-24
- **Primary completion:** 2020-09-09
- **Final completion:** 2020-09-24
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2020-10-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04505787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04505787, "S-flurbiprofen Bioavailability Trial to Compare a Newly Developed Patch vs. a Marketed Tablet". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04505787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*